Arrowhead ResearchARWR
Recorded

Arrowhead Research 2026 Q4 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ4 2026Duration1 hr 9 minParticipants20

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals conference call. Throughout today's recorded presentation, all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions. I will now hand the conference call over to Vince Anzalone, Senior Vice President of Investor Relations for Arrowhead.

Vincent AnzaloneSVP of Investor Relations

Please go ahead, Vince. Good afternoon, and thank you for joining us today to discuss Arrowhead's results for its 2026 fiscal year ended September 30, 2026.

Vincent AnzaloneSVP of Investor Relations

With us today from management are President and CEO, Dr. Chris Anzalone, who will provide an overview; Andy Davis, Senior Vice President and Head of the Global Cardiovascular Franchise, who will provide an update on commercialization activities; Dr. James Hamilton, Chief Medical Officer and Head of R&D, who will discuss our development programs; and Dan Apel, Chief Financial Officer, who will give a review of the financials. Following management's prepared remarks, we will open the call to questions. Before we begin, I would like to remind you that comments made during today's call contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Vincent AnzaloneSVP of Investor Relations

All statements other than statements of historical fact are forward-looking statements and are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and our quarterly reports on Form 10-Q. I'd now like to turn the call over to Chris.

Christopher AnzalonePresident and CEO

Thanks, Vince. Good afternoon, everyone. Thank you for joining us today. Arrowhead has fundamentally changed over the past 12 months. Where there was once a company that relied solely on great scientific promise, there is now a company that is beginning to translate promise into real patient outcomes and the potential for durable shareholder value growth. We are building a commercial business around REDEMPLO. We have delivered the pivotal data we believe is needed to pursue a much larger market in severe hypertriglyceridemia, or SHTG, and we have demonstrated new capabilities that substantially expand what our RNAi platform can do. I believe we approach 2027 with the strongest combination of near-term commercial opportunity and scientific capability in our history. For the long term, we intend Arrowhead to become a substantial pharmaceutical company that introduces important new medicines into the market virtually every year.

Christopher AnzalonePresident and CEO

We believe we have demonstrated that we have the platforms and development capabilities to do this, and the result could be an engine that improves innumerable patient lives and creates substantial value. First things first. We need to build a commercial presence that matches the excellence we have built in discovery and development, and we need to demonstrate that we are capable of building out a new market, finding the patients who could benefit from our medicines, and growing a profitable business. Simply put, commercial progress with REDEMPLO is critical. We are focused on continued success serving the FCS market, planning a rapid launch into SHTG, and positioning Arrowhead to maximize the SHTG market opportunity. Of course, revenue levels, growth, and profitability will ultimately be the only metrics that matter when assessing how we are doing with REDEMPLO.

Christopher AnzalonePresident and CEO

However, that will not tell the full story until after the first several quarters of our planned SHTG launch, as payer policies are being worked out, coverage is being secured, and provider outreach is initiated. During this period, we will regularly refer to three metrics that we believe capture the breadth and depth of early market penetration. They are: one, total number of new-to-brand patient prescriptions; two, number of distinct prescribers writing prescriptions; and three, number of lives covered on payer formularies. We believe there are large pools of patients who can benefit from REDEMPLO, and these three metrics are intended to reflect how well we are building pipes to reach them. We launched into the narrow FCS market about 11 months ago and are still in the pipe-building phase. This work has progressed well.

Christopher AnzalonePresident and CEO

As of September 30, we had 950 new-to-brand patient prescriptions, representing a 63% increase over the prior quarter end. This growth rate continues to increase rapidly, as we have added another 300 since then. At September 30, over 640 distinct individual prescribers wrote first-time prescriptions, and that number has grown to over 860 since then. There are now over 160 million lives covered in payer formularies in the U.S. We are seeing strong demand for REDEMPLO and continue to work with payers to increase the rate at which prescriptions are converted to paid shipments. This is still a choke point, and there is substantial work to do, but we are off to a good start. The pipes we are laying are critical for the FCS market and, importantly, directly applicable to the next stage of our business in SHTG.

Christopher AnzalonePresident and CEO

We intend to enter SHTG with an organization that already understands the medicine, its prescribers, and the practical work needed to get patients on treatment. Let's now look forward. We are preparing aggressively for a potential U.S. launch in SHTG in the second quarter of 2027, subject to successful FDA review and approval. The FDA granted plozasiran entry into the Split Real-Time Application Review, or STAR, pilot program for our planned SHTG supplement. STAR provides a six-month priority review framework and the possibility of action earlier than the formal goal date. We submitted our sNDA on November 2, so we expect to receive our PDUFA date over the next 50 days or so. We are very optimistic about the potential for this launch. We believe the clinical profile, the unmet need, and the capabilities we are building position REDEMPLO to become the leading treatment in this market.

Christopher AnzalonePresident and CEO

That conviction begins with data. In July, we announced that SHASTA-3 and SHASTA-4 met their primary endpoint and every pre-specified secondary endpoint. The detailed results presented at the European Society of Cardiology Congress in August and at the American Heart Association just last weekend reinforced the consistency of plozasiran's activity. Median triglyceride reductions from baseline were 79% and 81% at month 12. In the pooled analysis, cumulative acute pancreatitis events were reduced by 78% versus placebo across the broad SHTG population studied, with an impressive 100% reduction in patients at the highest risk of acute pancreatitis. These are results that we believe can change treatment expectations. Physicians see patients whose triglycerides remain dangerously elevated despite existing approaches.

Christopher AnzalonePresident and CEO

Our goal is to deliver those physicians a medicine that can produce deep, sustained reductions with a simple quarterly injection, supported by evidence of fewer acute pancreatitis events in the SHASTA-3 and 4 studies. We believe that is a powerful proposition for patients and payers alike. We continue to describe the profile we are pursuing as safe, simple, and strong. Safe reflects the favorable tolerability observed in all our studies, no increase in liver fat, no hypersensitivity, and no notable changes in liver values. Simple reflects a fixed 25 milligram dose administered once every three months. We don't expect to need to monitor liver enzymes, and there will be no need to titrate the dose up. Strong reflects the depth of triglyceride lowering and the pancreatitis results. The FDA will determine the final SHTG label, but we have a high degree of confidence in this medicine.

Christopher AnzalonePresident and CEO

We continue to see the potential for REDEMPLO to generate $3 billion-$4 billion in annual U.S. sales over time in SHTG. These are large numbers, but we see many ways to get there. While there are thought to be 3 million to 3.5 million people in the U.S. with TGs greater than 500 milligrams per deciliter, we believe the early adopters will be the population at highest risk within this group. This is comprised of those patients with TGs greater than 880 without a history of pancreatitis, and those with TGs greater than 500 that have a history of acute pancreatitis. Together, we believe this population totals almost 1 million people in the U.S., and their enhanced risk of acute pancreatitis would suggest that they are in real need of treatment.

Christopher AnzalonePresident and CEO

In SHASTA-3 and 4, the number of patients needed to treat in order to prevent a single acute pancreatitis event was nine in patients with TGs greater than 880 without a history of pancreatitis and those with TGs greater than 500 and a history of pancreatitis. Within that latter group alone, the NNT was only three. These are very compelling numbers, and keep in mind that this is just after one year. We would expect those NNTs to decrease further over longer treatment periods. Our data suggests that this patient population could benefit from REDEMPLO, but a valid question is how long it will take to educate patients and providers about the need to treat. There is clearly already some appreciation for this. For instance, we believe that around 1 million people with TGs greater than 500 are on prescription fish oils.

Christopher AnzalonePresident and CEO

This suggests to us that providers already have an urgency to treat TG levels for at least these patients. Remember that these fish oils only reduce TGs by 20%-30%, while REDEMPLO reduced TGs by around 80% from baseline in SHASTA-3 and SHASTA-4. Outside the U.S., our business is advancing as well. REDEMPLO became available for prescription, dispensing, and reimbursement in Germany in August, following the European Commission's June authorization. In addition, in October, the U.K. Medicines and Healthcare Products Regulatory Agency, or MHRA, authorized REDEMPLO in the United Kingdom for adults with FCS, and the U.K. National Institute for Health and Care Excellence, or NICE, issued guidance recommending funding in England and Wales. These milestones expand the foundation of our global cardiometabolic business. Besides our commercial build-out, our discovery engine has delivered two important clinical advances.

Christopher AnzalonePresident and CEO

In September, ARO-DIMER-PA demonstrated that one RNAi molecule can silence both PCSK9 and APOC3 in people with mixed hyperlipidemia. That opens an important new approach to ASCVD due to mixed hyperlipidemia and gives us a basis for developing additional medicines that address more than one disease driver at a time. Then in October, ARO-MAPT produced substantial and sustained reductions in tau measured in the cerebrospinal fluid after subcutaneous administration. We view this as early clinical validation of our ability to deliver RNAi across the blood-brain barrier. The opportunity to address CNS targets with an injection under the skin could dramatically expand the diseases we can pursue. I do not think this breakthrough can be overstated. We intend to move decisively to build on these results. This is the model we have been building for years.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day